Search For "clinical trial"
Bharat Biotech gets SEC approval for phase 3 clinical trials of COVID boos
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): The Subject Experts Committee (SEC) of the Drug Controller General of India (DCGI) on Wednesday granted approval to Bharat Biotech for conducting intranasal phase 3 trials and heterologous trials for COVID-19 booster intranasal vaccine for those who hav
Read More
SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose
Updated : 4 years, 2 months ago IST
New Delhi [India], January 4 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech's application for clinical trials of its intranasal Covid vaccine as a booster or a third dose.
Read More
Covaxin found to be safe, immunogenic in 2-18 age group in phase 2, 3 stud
Updated : 4 years, 2 months ago IST
Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.
Read More
Biological E gets approval to conduct trials of Corbevax as booster dose
Updated : 4 years, 2 months ago IST
New Delhi [India], December 29 (ANI): The Drug Controller General of India (DCGI) has given approval to the Hyderbad-based pharmaceutical company Biological E to conduct phase 3 clinical trials of its COVID-19 vaccine Corbevax as a booster dose, said sources.
Read More
Optimus Pharma granted permission for restricted use under emergency situa
Updated : 4 years, 2 months ago IST
Hyderabad (Telangana) [India], December 28 (ANI/PNN): Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.
Read More
Bharat Biotech seeks DCGI's approval for its intranasal COVID-19 booster d
Updated : 4 years, 2 months ago IST
New Delhi [India], December 20 (ANI): As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted the phase 3 clinical trial application to the Drugs Controller General of India (DCGI) to get approval for the booster dose
Read More
No recommendations for COVID-19 booster dose by SEC: Sources
Updated : 4 years, 3 months ago IST
New Delhi [India], December 11 (ANI): The Subject Expert Committee (SEC) under Central Drugs Standard Control Organization (CDSCO) has said COVID-19 that booster doses cannot be recommended without clinical trials.
Read More
Antibody measurement promises smaller, quicker clinical vaccine trials: US
Updated : 4 years, 3 months ago IST
Washington [US], December 8 (ANI/Sputnik): Antibody measurements shortly after people were vaccinated against COVID-19 revealed the potential for speedier clinical trials of new vaccine candidates with fewer participants, the National Institutes of Health (NIH) said.
Read More
Daytime meals might reduce health problems associated with night shift wor
Updated : 4 years, 3 months ago IST
Washington [US], December 4 (ANI): According to a small clinical trial by the National Institutes of Health, eating only during the daytime might prevent higher glucose levels for night shift workers.
Read More
COVID-19 vaccination for children: CDSCO approved ZyCoV-D for restricted u
Updated : 4 years, 3 months ago IST
New Delhi [India], November 30 (ANI): The Interim Phase II, III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated in the meeting of the Subject Expert Committee (SEC) on August 28 and October 11, informed Ministry of Health an
Read More
Lancet Infectious Diseases study compare well with phase 3 clinical trials
Updated : 4 years, 3 months ago IST
New Delhi [India], November 25 (ANI): Commenting on the study of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obt
Read More
Bugworks Research announces the first in Human Phase 1 Study of BWC0977 fo
Updated : 4 years, 4 months ago IST
Bengaluru (Karnataka) [India]/ Saratoga (California) [US]/ Adelaide [Australia], November 8 (ANI/PRNewswire): Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoiso
Read More